Vol. 4, Issue 12, Part G (2018)

Background and Objectives: Urticaria refers to a temporary condition characterized by distinct, superficial erythematous or pale swellings of the dermis. These swellings are typically accompanied by intense pruritus and are often accompanied by a surrounding red flare, occasionally accompanied by angioedema. The objective of this study was to evaluate the efficacy and safety evaluation of Omalizumab as a therapeutic intervention for Chronic Spontaneous Urticaria.

Material and Methods: This study employed a non-probability sampling method known as convenience sampling. This study utilized a sample size of 25 patients. The present investigation was conducted from October 2017 to September 2018. The investigation was carried out at the Department of Dermatology, Sambhram Institute of Medical Sciences and Research, Bangalore, Karnataka, India.

Results: There was no observed correlation between the duration of time, the quantity of urticarial lesions, and the frequency of urticaria episodes each week. The inference was formed based on the results of the paired t-test. The efficacy of Inj. Omalizumab in illness management has been demonstrated. There was a significant and consistent improvement in the UAS7 score from the pre-treatment to treatment week12. During the follow-up period, there was a marginal increase in the UAS7 score, but the efficacy of Omalizumab was not statistically significant. There was no notable enhancement in the UAS7 score following the therapy period. However, there is variation in the responses across individuals within the research population. The findings of this study align with the research conducted by Maurer et al., which demonstrated a consistent enhancement in the UAS7 over the course of the treatment period.

Conclusion: The wheals score of UAS7 experienced a significant decrease, whereas the itch severity level remained unchanged during the follow-up period. A single patient experienced pseudoscleroderma subsequent to the initial administration of omalizumab. The subcutaneous administration of Omalizumab 300mg can be administered once every 4 weeks, unless there are specific contraindications.